Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
BACKGROUND
The clinical and economic benefits associated with apixaban treatment have been established in clinical trials and published economic evaluations. The benefits associated with apixaban could extend to improving hospital efficiencies, potentially influencing hospital resource use, and bed days. The objective of this study is to estimate the impact of 6-month treatment with apixaban vs low molecular weight heparin/vitamin k antagonist (LMWH/VKA) on hospital resource use among patients with venous thromboembolism (VTE).


METHODS
A model was developed to assess the impact of apixaban vs LMWH/VKA for treatment of VTE and prevention of recurrences on hospital resource use and costs. Resource use items included total hospitalizations, length of stay (LOS), and emergency department (ED) visits, estimated for all incident VTE patients in the UK over a 5-year time horizon. Rates of hospitalizations, ED visits, and LOS associated with recurrent VTE, major, and clinically relevant non-major bleeding were obtained from the AMPLIFY trial; costs were obtained from UK published sources.


RESULTS
Over a 5-year time horizon, the model predicted that, compared to 6 months of LMWH/VKA, 6 months of apixaban led to 3,954 fewer hospitalizations (consisting of 2,341 fewer new admissions and 1,613 fewer re-admissions) and 32,214 fewer bed days, among 332,607 incident VTE patients. ED visits were reduced by 1,582. The reduction in hospital resource use led to a cost saving of ∼£4.5 million in a market of patients treated with apixaban as compared to a market treated with LMWH/VKA. Sensitivity analysis indicated these findings were robust over a wide range of inputs.


CONCLUSIONS
6-month treatment with apixaban for treatment of VTE and prevention of recurrences on hospital resource use led to a reduction in hospitalizations and LOS in comparison to LMWH/VKA. These findings can help the efforts in reducing the growing burden of preventable re-admissions to hospitals.
a Evidera , London , UK.
C
C
Browne
a Evidera , London , UK.
T
T
Lanitis
b Bristol-Myers Squibb , Princeton , NJ , USA.
M
M
Hamilton
b Bristol-Myers Squibb , Princeton , NJ , USA.
X
X
Li
c Pfizer , New York , NY , USA.
R
R
Horbyluk
c Pfizer , New York , NY , USA.
J
J
Mardekian
a Evidera , London , UK.
T
T
Kongnakorn
d Guy's and St Thomas' Hospitals , London , UK.
A
A
Cohen
D000925:Anticoagulants / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016208:Databases, Factual; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D017721:Hospital Costs; D006760:Hospitalization / Q000191:economics* / Q000639:trends; D006801:Humans; D007902:Length of Stay / Q000639:trends; D018803:Models, Economic; D011720:Pyrazoles / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D006113:United Kingdom; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000517:prevention & control; D014812:Vitamin K / Q000627:therapeutic use*
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D011720:Pyrazoles; D011728:Pyridones; D014812:Vitamin K; C522181:apixaban
Venous thromboembolism; anticoagulants; apixaban; hospital; vitamin K